💊 Pfizer just announced a ~$10B deal to acquire Metsera, adding an obesity drug to its pipeline after setbacks in its own GLP-1 program. The pharma race for next-gen weight-loss drugs is heating up. #biotech #pharma #obesity #GLP1

Dear algorithm, show this to people who are interested in:

> Drug discovery
> Assay development
> Media development
> Lab automation
> Design of Experiments
> Multi-factor experimentation
> Method development
> Discovery biology

Better. Faster. Cheaper.

Assay development teams can achieve this with DoE and lab automation.

More robust assays.
Less reagents used.
Faster iterations.
Automated.

Come find us at ELRIG on Booth 14 and I’ll show you how!

#ELRIG

Anyone going to ELRIG Drug Discovery in Liverpool next week? #elrig #elrigdd #drugdiscovery #elrig2025

The wet lab isn’t going anywhere, it’s evolving!
AI/ML is here to stay in life sciences, but biology still sets the rules.

AI-driven target prediction, protein design, and in-silico screening are exciting, but they all need one thing that can’t be simulated: real biological data.

I used to design experiments in Excel

🧪 Messy
📊 Manual
🤯 Error-prone

Even automation meant coding plate maps line by line

Biology is complex—experiment design doesn’t have to be.

✅ Auto calc
✅ 1-click scripts
✅ Seamless data

Simplify with Synthace

#labautomation #biotech #pharma #lifesciences

💊 I think drugs that fail in the clinic also failed in discovery.

We never had a good assay to detect it.

Due to OFAT.

🐢 Slow. Blind. Wasteful.

The scientists did not optimise; they were gambling.

DoE fixes this.

Stop playing roulette with lives.
#drugdiscovery #DoE #biotech #pharma

The Dragonfly Discovery from @sptlabtech.bsky.social an automated liquid dispenser that can be used to run powerful multifactorial experiments.

This is how you generate high-throughput insights.

The future of drug discovery is faster, smarter, smaller. 🧬🤖 #biotech #labautomation #drugdiscovery

Any scientists here? 🙋‍♂️

#scientists #biologist #researcher

🧬 Most failed drugs weren’t bad ideas.

They were greenlit by weak, noisy, or misaligned assays.

We don’t have a molecule problem.

We have a signal fidelity problem.

And it's costing us billions.

1 / 2

#DrugDiscovery #AssayDevelopment #Biotech